Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidance Full Year 2023 Total Revenues of$1.05 billion, which was the mid-point of guidance Fourth Quarter 2023 Net Loss of $50 million and Adjusted EBITDA of$3 million Issues Q1 2024 and FY 2024 guidance GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the quarter and year ended December 31, 2023. "Emergent has a long history o ...